MentionFox
Home › IPO pipeline › GenEmbryomics Ltd
IPO filings · Form S-1, F-1, 424B4, RW

GenEmbryomics Ltd IPO

GenEmbryomics Ltd's initial public offering: every registration filing, amendment, final prospectus and withdrawal, with the facts quoted from the filings and each one linked.

StatusWithdrawn
TickerXGEN
ExchangeNasdaq Capital Market
First filed2025-02-20
Filings4

GenEmbryomics Ltd filed a Form F-1 registration statement for an initial public offering on 2025-02-20. It has amended it 2 times. It asked for the registration statement to be withdrawn on 2025-04-23. Each fact below is quoted from the filing named with it.

What the filings say

Listing

We have reserved the ticker symbol "XGEN" and we intend to apply to the Nasdaq Stock Market to have the Ordinary Shares listed on the Nasdaq Capital Market under the symbol “XGEN.” No assurance can be given that our application will be approved.From the F-1/A filed 2025-03-25

Use of proceeds

We intend to use the net proceeds we receive from this offering as follows:From the F-1/A filed 2025-03-25

Net loss or income

We have incurred operating losses since our inception with a net loss of approximately $1.98 million for the fiscal year ended June 30, 2024, and have a net deficit of current assets over current liabilities at June 30, 2024.From the F-1/A filed 2025-03-25

Withdrawal

The Company is withdrawing the Registration Statement because the Company has not sold securities pursuant to the Registration Statement withdrawn hereby.From the RW filed 2025-04-23

Timeline

FiledWhat it isFiling
2025-02-20Registration statement filed (foreign issuer)F-1
2025-03-17Registration statement amended (foreign issuer)F-1/A
2025-03-25Registration statement amended (foreign issuer)F-1/A
2025-04-23Request to withdraw a registration (Form F-1)RW

Tools for this story

Each opens in a new tab, filled in for GenEmbryomics Ltd. With no account yet, you sign up free and land on the result.

Where this comes from

A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.

Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/ipo/genembryomics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
GenEmbryomics Ltd IPO (XGEN, Nasdaq Capital Market): registration withdrawn. MentionFox, 2026-09-27. https://mentionfox.com/ipo/genembryomics